Moreover, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been clinically approved as antidiabetic agents and have been shown to suppress appetite, which has resulted in their use in clinical settings as anti-obesity drugs [4]. This evidence concerns the gene GLP1R and Obesity.